Bupivacaine

Search ⌘K Suggest Edit Sign in Medical uses Safety profile Pharmacology Chemistry History and development Society and culture Research directions References Fact-checked by Grok 4 months ago Bupivacaine Bupivacaine is a potent, long-acting amide-type local anesthetic that reversibly binds to voltage-gated sodium channels in neuronal membranes, thereby inhibiting the propagation of nerve impulses and producing regional anesthesia and analgesia.[1][2] It is on the World Health Organization's List of Essential Medicines. First synthesized in 1957, it was approved by the U.S. Food and Drug Administration in 1972 under the brand name Marcaine for use in various surgical and obstetric procedures.[1] Chemically, bupivacaine is a homologue of mepivacaine with the molecular formula C₁₈H₂₈N₂O, featuring an aromatic ring, an amide linkage, and a tertiary amine, which contribute to its high lipid solubility and prolonged duration of action compared to shorter-acting agents like lidocaine.[3][2] The mechanism of action of bupivacaine involves stabilizing neuronal membranes by preventing the influx of sodium ions during depolarization, which halts the generation and conduction of action potentials; this effect is concentration-dependent and more pronounced in sensory nerves than motor nerves at clinical doses.[1] Due to its slow dissociation from sodium channels, bupivacaine exhibits a longer duration of anesthesia—typically 4 to 8 hours without vasoconstrictors and up to 12 hours with epinephrine—making it suitable for extended procedures.[1][3] It is primarily metabolized in the liver via N-dealkylation and hydroxylation, with a plasma half-life of approximately 2.7 hours in adults, and is excreted mainly by the kidneys.[3] Bupivacaine is indicated for local infiltration, peripheral nerve blocks, epidural and spinal anesthesia, caudal blocks, retrobulbar blocks, and dental procedures, often in concentrations of 0.25%, 0.5%, or 0.75%, with or without epinephrine to prolong effects and reduce systemic absorption.[3] It is commonly employed in surgical settings for postoperative pain management, labor analgesia, cesarean sections (using lower concentrations), and orthopedic or abdominal surgeries, where its extended action minimizes the need for frequent redosing.[1] Liposomal formulations, such as Exparel approved in 2011, extend its release for up to 72 hours, enhancing multimodal analgesia in soft tissue or joint procedures.[4] Maximum recommended doses range from 175 mg (without epinephrine) to 225 mg (with epinephrine) for most adults, with adjustments for elderly, pediatric, or debilitated patients to avoid toxicity.[3] Despite its efficacy, bupivacaine carries significant risks, including central nervous system toxicity (e.g., seizures, coma) and cardiovascular depression (e.g., arrhythmias, hypotension) due to its high affinity for cardiac sodium channels, particularly with the 0.75% concentration, which is contraindicated for obstetric epidural use following reports of maternal cardiac arrests.[1][3] Other adverse effects may include methemoglobinemia, chondrolysis with intra-articular infusion, and hypersensitivity reactions; systemic toxicity is managed with lipid emulsion therapy.[3] Contraindications include known hypersensitivity to amide anesthetics, severe conduction disturbances, and active infection at the injection site.[1] Monitoring vital signs and avoiding intravascular injection are critical during administration.[3] Medical uses Indications Bupivacaine is primarily indicated for the production of local or regional anesthesia and analgesia in surgical, dental, oral surgery, diagnostic, therapeutic, and obstetrical procedures.[3] It is commonly used via local infiltration for minor procedures, peripheral nerve blocks for upper and lower extremity surgeries such as orthopedic interventions, and retrobulbar blocks for ocular surgery, with specific concentrations like 0.25% for infiltration and 0.75% reserved for retrobulbar use.[3] In obstetrics, it supports epidural and caudal anesthesia for labor and delivery, including cesarean sections, though concentrations above 0.5% are not recommended due to safety concerns.[3] Dental applications include infiltration injections and nerve blocks in adults using 0.5% formulations with epinephrine.[3] For postoperative pain management, bupivacaine plays a key role through single-shot peripheral nerve blocks or continuous infusions via catheters, particularly in procedures like joint replacements and abdominal surgeries, helping to provide extended analgesia.[3] This approach is especially valued in multimodal regimens to minimize opioid requirements, with formulations such as liposomal bupivacaine extending relief up to 72 hours.[5] In oral and maxillofacial surgery (OMFS), Exparel is used via infiltration for procedures such as third molar (wisdom tooth) extractions, dental implants, orthognathic surgery, and cleft palate repair. Clinical studies and real-world data, including phase 3 trials in third molar extraction, show it reduces postoperative opioid consumption (e.g., lower morphine milligram equivalents and refill rates), enables higher same-day discharge rates, and supports opioid-sparing protocols. These align with AAOMS efforts to minimize opioid prescribing, especially in young adults at risk for first opioid exposure. In some pediatric craniofacial procedures, cohorts have reported no postoperative opioids needed. Exparel is administered as a single-dose local infiltration at the end of the procedure, after initial anesthesia (e.g., lidocaine nerve blocks) and surgical closure, due to its slow onset. A 20-minute delay after non-bupivacaine anesthetics is recommended. It uses a 22-25 gauge needle, with slow injections and frequent aspiration to avoid intravascular administration. Multiple small-volume injections (0.5-2 mL each, spaced 1-1.5 cm apart) ensure coverage, as it diffuses less than plain bupivacaine. For bilateral third molar extractions, a common dose is 133 mg (10 mL undiluted), divided between sites (e.g., 4 mL maxilla, 6 mL mandible total). Maxilla: 2 mL per side (total 4 mL), infiltrated at 2 points per socket (submucosal and supraperiosteal, 6-8 mm apart) near the apex, 1 mL each, or into the buccal aspect. Mandible: 3 mL per side (total 6 mL), after flap closure—e.g., 4 points along buccinator attachment (0.5 mL each, 5 mm deep), plus 2x0.5 mL at subperiosteal reflection (1.5 cm deep, withdrawn needle for column effect); or 4 mL per side as 1 mL injections along lateral mandible. Maximum dose: 266 mg (20 mL). It may be diluted for volume. Often part of multimodal analgesia to minimize opioids. Exparel's FDA-approved indications extend beyond general bupivacaine uses. It is approved for producing postsurgical local analgesia via infiltration in patients aged 6 years and older, and for regional analgesia in adults via interscalene brachial plexus nerve block (for upper extremity surgeries such as total shoulder arthroplasty), sciatic nerve block in the popliteal fossa (for foot, ankle, and lower leg procedures), and adductor canal block (for knee and medial lower leg surgeries). These expansions, granted in recent years, support its application in a wider range of orthopedic and soft-tissue procedures. Exparel is commonly employed in major orthopedic surgeries, including total hip and knee replacements, as part of multimodal pain management to deliver extended postoperative analgesia (up to 72 hours) and reduce opioid requirements, aligning with efforts to address the opioid crisis through non-opioid alternatives. Under the Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act, Medicare has enhanced reimbursement for Exparel to promote non-opioid options. Prior to 2025, separate reimbursement was available in ambulatory surgical centers (ASCs) via temporary HCPCS code C9290 since 2019, but it was frequently packaged into payments in hospital outpatient departments (HOPDs). Effective January 1, 2025, CMS introduced permanent HCPCS code J0666 (Injection, bupivacaine liposome, 1 mg), enabling separate payment at average sales price plus 6% (ASP + 6%) across all outpatient settings, including both HOPDs and ASCs. In contrast, Exparel costs for inpatient procedures continue to be bundled into Diagnosis-Related Group (DRG) payments. Off-label, bupivacaine is employed in intrathecal administration for refractory chronic nonmalignant pain syndromes, often in combination with opioids via implantable pumps, to improve pain control, activity levels, and quality of life in patients unresponsive to conventional therapies.[6] Introduced clinically in the early 1960s following its synthesis in 1957, bupivacaine gained prominence for obstetrical anesthesia due to its long duration of action compared to earlier agents like lidocaine.[1] Today, its use underscores a shift toward non-opioid alternatives in perioperative care, reducing reliance on systemic analgesics amid the opioid crisis.[5] Administration and dosage Bupivacaine is administered via several routes depending on the clinical procedure, including local infiltration, epidural, spinal (intrathecal), peripheral nerve blocks, and occasionally topical application for specific uses such as post-tonsillectomy analgesia.[1] Intravenous regional anesthesia (Bier block) is generally not recommended due to risks of cardiac arrest and death if systemic absorption occurs rapidly upon tourniquet release.[3] Dosage guidelines vary by route, concentration, patient factors, and whether combined with adjuvants like epinephrine (1:200,000) to reduce vascular absorption and prolong duration. The following table summarizes representative dosage ranges for adults, based on average body weight and procedure duration; maximum doses should not exceed 2-3 mg/kg without epinephrine or 3 mg/kg with it, with total daily limits around 400 mg.[7][1] Route Concentration Typical Volume Maximum Dose (mg) Notes Local Infiltration 0.25-0.5% Up to 70-90 mL 175 (plain); 225 (with epinephrine) For postoperative analgesia; adjust for tissue vascularity.[7] Epidural 0.5-0.75% 10-20 mL incremental Up to 225 For labor or surgery; test dose of 3 mL 0.5% with epinephrine first; not 0.75% in obstetrics.[3][7] Spinal (Intrathecal) 0.75% (7.5 mg/mL) 0.8-1.6 mL 6-12 Hyperbaric solution; e.g., 6 mg for vaginal delivery, 12 mg for lower abdominal procedures.[8] Peripheral Nerve Block 0.25-0.5% Varies by site (e.g., 20-30 mL for brachial plexus) Up to 175-225 For surgical anesthesia; duration 4-8 hours.[1] Topical (e.g., tonsillar swab) 0.5% (5 mg/mL) 4 mL total 20 Limited to specific ENT procedures; low systemic absorption.[9] Dosages must be adjusted for patient-specific factors, including reduced amounts in elderly or debilitated individuals due to higher peak plasma levels and slower clearance, and caution in those with moderate to severe hepatic impairment owing to primary liver metabolism, or renal impairment affecting metabolite excretion.[1][7] Adjuvants such as epinephrine extend effect by vasoconstriction, while others like clonidine or dexamethasone may be added for further prolongation in nerve blocks.[1] Bupivacaine is available in preservative-free formulations (e.g., single-dose vials or ampules) preferred for epidural, spinal, or caudal routes to minimize neurotoxicity risks, whereas multi-dose vials may contain preservatives like methylparaben, which should be avoided in neuraxial administration due to potential allergic reactions.[7][8] During administration, especially for epidural or nerve blocks, continuous monitoring of vital signs (ECG, oxygen saturation, blood pressure) is essential to detect systemic absorption, with aspiration for blood or cerebrospinal fluid before injection and use of test doses to rule out intravascular or intrathecal placement.[3][7] Safety profile Contraindications Bupivacaine is contraindicated in patients with known hypersensitivity to bupivacaine, other amide-type local anesthetics, or components of the formulation, as severe allergic reactions may occur.[10] It is also absolutely contraindicated for obstetrical paracervical block anesthesia due to reports of fetal bradycardia, acidosis, and death.[10] Additionally, intravenous regional anesthesia (Bier block) is contraindicated because of the risk of cardiac arrest and death following unintentional intravascular injection.[10] For spinal anesthesia specifically, bupivacaine is contraindicated in cases of severe hemorrhage, severe hypotension or shock, arrhythmias such as complete heart block that restrict cardiac output, local infection at the lumbar puncture site, or septicemia.[11] Relative contraindications include active central nervous system infection or sepsis, where the risk of disseminating infection outweighs benefits.[1] Severe liver disease is a relative contraindication due to impaired hepatic clearance of amide anesthetics, potentially leading to increased systemic toxicity.[1] Hypovolemia and impaired cardiac function, including heart block, require caution as they may exacerbate hypotension and cardiovascular depression.[1] Concurrent use with certain antiarrhythmics, particularly Class III agents like amiodarone, is relatively contraindicated owing to potential additive effects on cardiac conduction and increased risk of arrhythmias, although specific interaction studies are limited.[12] Specific warnings advise against use in patients prone to malignant hyperthermia, as systemic absorption could complicate management, though local anesthetics like bupivacaine are generally considered safe triggers are absent.[1] For porphyria, bupivacaine is not an absolute contraindication but warrants caution in acute intermittent or variegate types due to potential hepatic metabolism concerns, despite clinical evidence supporting its safety in regional anesthesia.[13] Intra-articular continuous infusion and the 0.75% concentration for obstetric anesthesia are also contraindicated based on toxicity risks.[1] The contraindications for bupivacaine have evolved since its introduction in 1965, with significant updates in the late 1970s and 1980s following reports of profound cardiac toxicity, including refractory ventricular arrhythmias and arrests, particularly associated with the 0.75% formulation in obstetrics.[14] In 1979, Albright's editorial reported 5 cases of cardiac arrest linked to bupivacaine, contributing to growing concerns. Subsequent FDA reports in 1983 documented 49 cardiac arrests and 21 deaths, prompting the FDA to issue a black box warning prohibiting the 0.75% solution for epidural or caudal blocks in obstetrics, which reduced toxicity incidence.[15] These changes emphasized slower dissociation from cardiac sodium channels as a key factor in bupivacaine's cardiotoxicity compared to other agents. As of 2025, safety profiles remain consistent with established guidelines, with continued emphasis on lipid emulsion availability for LAST management.[1] Adverse effects Bupivacaine administration can result in local adverse effects at the injection site, such as tissue irritation manifesting as pain, erythema, or swelling, which typically resolve spontaneously. Injection site infections, including abscess formation, represent a potential complication due to procedural factors rather than the drug itself.[16] A rare but serious local effect associated with intra-articular use is postarthroscopic glenohumeral chondrolysis, characterized by rapid and irreversible cartilage degeneration in the shoulder joint, often linked to continuous infusions rather than single doses. In vitro and animal studies demonstrate that bupivacaine at concentrations of 0.5% or higher induces chondrocyte toxicity through mechanisms involving apoptosis and reduced proteoglycan synthesis.[17][18] Systemic adverse effects arise from elevated plasma concentrations leading to local anesthetic systemic toxicity (LAST), with central nervous system (CNS) manifestations appearing first as excitatory symptoms including circumoral tingling, agitation, restlessness, dizziness, tinnitus, and blurred vision, potentially progressing to seizures, coma, and respiratory arrest. Cardiovascular toxicity follows or co-occurs, featuring initial hypertension and tachycardia, then hypotension, conduction delays, ventricular arrhythmias, myocardial depression, and refractory cardiac arrest. Bupivacaine demonstrates greater cardiotoxicity than other amide local anesthetics such as lidocaine or ropivacaine, attributable to its higher potency in blocking cardiac sodium channels and slower recovery from blockade, resulting in a narrower therapeutic window where CNS and cardiovascular toxicity thresholds overlap.[1][19][14] The overall incidence of LAST with bupivacaine is low, estimated at 1:1,000 to 1:10,000 peripheral nerve blocks or epidural procedures, though higher in high-dose contexts like liposomal formulations or large-volume infiltrations, with severe LAST reported at approximately 0.3% (3 per 1,000) in clinical studies through 2024.[1][20][21] Allergic reactions to bupivacaine are uncommon, with true IgE-mediated anaphylaxis rare among amide-type local anesthetics; however, hypersensitivity to additives like methylparaben in multi-dose vials can mimic allergic responses. Methemoglobinemia, a blood disorder impairing oxygen transport, is infrequently reported with bupivacaine but has occurred in isolated cases, potentially exacerbated by oxidizing preservatives or concurrent agents, contrasting with its higher association with prilocaine.[1][22] Overdose management Local anesthetic systemic toxicity (LAST) from bupivacaine is recognized by its biphasic presentation, initially involving central nervous system (CNS) excitation such as agitation, tinnitus, perioral numbness, and seizures, followed by CNS depression manifesting as drowsiness, respiratory depression, and coma, which may progress to cardiovascular collapse and cardiac arrest.[23] This sequence underscores the urgency of early identification, as bupivacaine's high lipid solubility and protein binding contribute to its potent cardiotoxicity.[23] Immediate management prioritizes airway support and ventilation to ensure oxygenation and prevent hypoxemia or hypercarbia, which exacerbate toxicity; endotracheal intubation may be required for respiratory compromise.[23] The cornerstone intervention is intravenous lipid emulsion therapy using 20% Intralipid, administered as a 1.5 mL/kg bolus over 2-3 minutes (approximately 100 mL for adults over 70 kg), followed by an infusion of 0.25 mL/kg/min for 15-20 minutes, with repeat boluses if instability persists and a maximum total dose of 12 mL/kg.[24] Advanced cardiac life support (ACLS) protocols are modified for LAST: vasopressin is avoided due to risks of worsening cardiac output, epinephrine is limited to small doses (≤1 mcg/kg), and amiodarone is preferred for ventricular arrhythmias over other antiarrhythmics like lidocaine.[24][23] Supportive care includes benzodiazepines (e.g., midazolam or lorazepam) as first-line treatment for seizures to minimize metabolic acidosis from prolonged activity, with propofol used cautiously in low doses if needed; aggressive hyperventilation and sodium bicarbonate may be employed to correct acidosis, as it potentiates bupivacaine's cardiotoxic effects.[23] These strategies align with the 2020 American Society of Regional Anesthesia and Pain Medicine (ASRA) checklist and the 2020 American Heart Association (AHA) guidelines, which endorse lipid emulsion for life-threatening LAST.[24][25] Case reports through 2024, including pediatric instances of bupivacaine-induced LAST, continue to affirm the efficacy of prompt lipid rescue in achieving hemodynamic stability and recovery.[26][27] Use in special populations Bupivacaine is classified as FDA Pregnancy Category C, indicating that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans; it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.[11] Local anesthetics like bupivacaine rapidly cross the placenta and can cause varying degrees of maternal, fetal, and neonatal toxicity, including fetal bradycardia, when used for epidural, caudal, or pudendal block anesthesia.[10] It is contraindicated for obstetrical paracervical block anesthesia due to reports of fetal bradycardia, neonatal acidosis, and even death, but it may be used safely for epidural anesthesia during labor with lower concentrations (0.25% or 0.5%) administered in incremental doses of 3-5 mL (not exceeding 50-100 mg total) while maintaining the patient in a left lateral decubitus position to avoid aortocaval compression.[10] Bupivacaine is excreted into human breast milk, but the amount transferred is minimal, with studies showing that an exclusively breastfeeding neonate would ingest less than 1% of the maternal dose (relative infant dosage), posing low risk to the infant.[28] Use during lactation is considered acceptable if clearly needed, as no adverse effects on breastfed infants have been reported, though monitoring for potential sedation or other effects is advised.[29] In pediatric patients, bupivacaine is used for regional anesthesia such as caudal blocks during surgery, but dosing must be reduced due to immature hepatic metabolism and higher risk of systemic toxicity; the maximum recommended dose is 2-3 mg/kg (plain solution 2.5 mg/kg, with epinephrine 3 mg/kg) to avoid seizures or cardiovascular complications.[30] Safety and efficacy have not been fully established in children under 12 years per FDA labeling, necessitating careful monitoring and use only by experienced practitioners.[10] For elderly patients, particularly those with frailty, hypertension, or reduced physiological reserve, bupivacaine doses should be reduced by 20-50% commensurate with age and physical condition to account for prolonged elimination and increased risk of hypotension or toxicity; close monitoring of vital signs and renal function is essential, as the drug is substantially excreted by the kidneys.[31] In patients with renal impairment, dosage adjustments are recommended due to decreased clearance and heightened risk of adverse reactions.[10] Similarly, for hepatic impairment, reduced dosing and heightened monitoring are required because bupivacaine undergoes primary hepatic metabolism, leading to potential accumulation and toxicity in moderate to severe cases.[10] Caution is advised when using bupivacaine in patients with cardiac disease due to its proarrhythmic potential and risk of cardiac arrest from systemic toxicity, even at therapeutic doses; those with impaired cardiovascular function may be less able to compensate for hypotensive or arrhythmogenic effects.[32] Recent pharmacovigilance analyses highlight ongoing concerns for cardiotoxicity in vulnerable populations, including geriatric patients with frailty, emphasizing the need for individualized dosing and ECG monitoring.[33] Pharmacology Pharmacodynamics Bupivacaine is an amide-type local anesthetic that exerts its effects through reversible binding to voltage-gated sodium channels in neuronal membranes, thereby preventing sodium ion (Na⁺) influx and inhibiting the generation and propagation of action potentials. This blockade stabilizes the neuronal membrane by decreasing its permeability to Na⁺, which raises the threshold for electrical excitation and slows nerve impulse conduction. The drug preferentially targets open or activated sodium channels, demonstrating use-dependence where the blockade intensifies with higher frequencies of nerve stimulation.[1][2][34] The pharmacodynamics of bupivacaine are influenced by its physicochemical properties, including a pKa of 8.1, which results in approximately 15% of the drug being un-ionized at physiological pH (7.4), allowing membrane penetration while contributing to a relatively slow onset of action (typically 5-10 minutes for infiltration or nerve blocks). High plasma protein binding, around 95%, primarily to alpha-1-acid glycoprotein and albumin, prolongs its duration of action by limiting free drug availability for redistribution, enabling sensory and motor blockade lasting up to 8 hours depending on the site and dose. Bupivacaine exhibits stereoselectivity in its sodium channel interactions; the S-enantiomer (levobupivacaine) dissociates more rapidly from cardiac channels, conferring lower cardiotoxicity compared to the racemic mixture, while overall potency among amide local anesthetics follows the order bupivacaine > ropivacaine due to greater lipid solubility and channel affinity.[1][2][34][35] Bupivacaine produces a differential nerve block, preferentially affecting sensory fibers (Aδ and C fibers for pain and temperature) over motor fibers (Aα), attributable to differences in fiber diameter, myelination, and conduction velocity, with the order of functional loss being pain, temperature, touch, deep pressure, and finally motor function. However, systemic exposure can lead to cardiotoxicity via blockade of myocardial voltage-gated sodium channels (Naᵥ1.5), causing slowed conduction, prolonged QRS intervals, and reentrant arrhythmias due to the drug's high affinity and slow unbinding kinetics.[1][34] Pharmacokinetics Bupivacaine is absorbed into the systemic circulation at a rate dependent on the dose, concentration, route of administration, vascularity of the injection site, and the presence of vasoconstrictors such as epinephrine.[3] For epidural, caudal, or peripheral nerve blocks, peak plasma concentrations typically occur 30 to 45 minutes after injection, with levels declining gradually over 3 to 6 hours.[3] Systemic absorption is more rapid from highly vascularized sites like intercostal spaces compared to less vascular areas such as subcutaneous tissue, increasing the risk of toxicity with faster uptake.[3] The addition of epinephrine (1:200,000) slows absorption and reduces peak plasma levels by causing local vasoconstriction.[3] Following absorption, bupivacaine distributes widely throughout the body, with high concentrations accumulating in highly perfused organs such as the heart, lungs, liver, and brain.[3] It exhibits a large volume of distribution, approximately 73 L in adults, reflecting extensive tissue penetration.[36] Approximately 95% of bupivacaine in plasma is bound to proteins, primarily alpha-1-acid glycoprotein, with binding increasing during inflammation or stress due to elevated levels of this glycoprotein.[37] Bupivacaine crosses the blood-brain barrier and the placenta via passive diffusion, though the fetal-to-maternal plasma ratio is low (0.2 to 0.4), attributed to high protein binding and ionization differences.[3] Pharmacokinetic modeling after intravenous administration follows a three-compartment open model, with rapid initial distribution to central compartments followed by slower equilibration in peripheral tissues.[3] Bupivacaine undergoes primary metabolism in the liver through N-dealkylation, primarily via cytochrome P450 3A4 (CYP3A4), yielding piperidine metabolites such as 2,6-pipecoloxylidine (PPX).[37] PPX retains some anesthetic activity but is considerably less potent than the parent compound.[37] Additional hepatic conjugation with glucuronic acid contributes to metabolite formation.[3] The elimination half-life is approximately 2.7 hours in adults but is prolonged to 8.1 hours in neonates due to immature hepatic function.[3] Half-life may also extend in the elderly owing to reduced clearance.[3] Excretion of bupivacaine occurs predominantly via the kidneys, with only about 6% eliminated unchanged in urine; the remainder is excreted as metabolites.[3] Renal clearance is influenced by urinary pH and perfusion, with more unchanged drug excreted in acidic urine.[3] Total plasma clearance averages around 0.47 L/min in adults, though values can vary with factors like hepatic function and co-administration of drugs affecting CYP3A4.[38] Epinephrine co-administration can reduce systemic clearance by limiting absorption.[3] Chemistry Chemical structure and properties Bupivacaine is a synthetic amide local anesthetic with the IUPAC name 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide. Its molecular formula is C₁₈H₂₈N₂O, and the molecular weight is 288.43 g/mol.[2] The molecule features an amide linkage connecting a piperidine ring substituted at the 1-position with a butyl chain and at the 2-position with a carboxamide group, which is further linked to a 2,6-dimethylphenyl (xylidine) ring. Bupivacaine is administered clinically as a racemic mixture containing equal proportions of its levo- and dextro-enantiomers.[2] Physically, bupivacaine base appears as a white, odorless crystalline powder with a melting point of 107–108 °C. It exhibits a pKa of 8.1, indicating weak basicity, and a logP value of 3.4, reflecting its lipophilic nature that contributes to its membrane permeability. The hydrochloride salt form is freely soluble in water, achieving concentrations up to approximately 25 mg/mL, while the base itself has limited aqueous solubility.[2] Regarding stability, bupivacaine is sensitive to heat and light, particularly in solution form, where exposure can lead to degradation; it is recommended to store it protected from light at controlled room temperature (15–30 °C). Efforts in the 1990s focused on chiral separation to isolate the S-enantiomer, known as levobupivacaine, which demonstrated reduced cardiotoxicity compared to the racemate while maintaining anesthetic efficacy.[3][39] Formulations and preparations Bupivacaine hydrochloride is commercially available in standard injectable solutions at concentrations of 0.25%, 0.5%, and 0.75%, formulated as sterile, isotonic aqueous solutions for local and regional anesthesia.[3] These preparations are typically supplied in single-dose vials or ampoules, with volumes ranging from 10 mL to 30 mL depending on the concentration and intended use.[11] Formulations may include epinephrine (as bitartrate) at a concentration of 1:200,000 to provide vasoconstriction and prolong anesthetic effect, particularly for infiltration or nerve block applications.[3] For spinal anesthesia, hyperbaric solutions combine 0.75% bupivacaine hydrochloride with 8.25% dextrose to achieve the desired baricity and spread within the subarachnoid space.[40] Liposomal bupivacaine (Exparel) Exparel (bupivacaine liposome injectable suspension), developed by Pacira BioSciences, is a long-acting formulation of bupivacaine encapsulated in multivesicular liposomes using DepoFoam technology, enabling sustained release over up to 72 hours (with effects potentially lasting longer in some applications), reducing opioid requirements during the initial recovery period. Approved by the FDA in 2011 for single-dose infiltration to produce postsurgical local analgesia, its indications have expanded: in 2021 to include patients aged 6 years and older, and in 2023 to add administration as an adductor canal block and sciatic nerve block in the popliteal fossa in adults (in addition to the prior interscalene brachial plexus block). It is indicated for postsurgical local analgesia via infiltration in patients ≥6 years and regional analgesia via specific nerve blocks in adults; safety and efficacy are not established for other blocks. Exparel is administered as a single dose during surgery, often via wound infiltration or targeted blocks, sometimes combined with plain bupivacaine HCl (in ratios not exceeding 1:2 mg) for immediate onset while providing prolonged coverage. Its pharmacokinetics feature an initial rapid onset, dual plasma peaks (at ~1 hour and 12-36 hours), and extended local effects, though systemic levels remain below toxic thresholds when dosed appropriately. The maximum recommended dose for infiltration in adults is 266 mg (20 mL of the 1.3% suspension), often diluted with preservative-free normal saline (e.g., to 60-80 mL or more) for improved distribution in larger surgical sites. Preparation and dilution: Prior to administration, invert the vial multiple times to resuspend the liposomal particles. Exparel can be used undiluted or diluted with 0.9% sodium chloride injection or lactated Ringer's injection. Avoid hypotonic solutions as they may compromise the formulation. Exparel is administered intraoperatively as a single dose by the surgeon under anesthesia. For surgical site infiltration, use a 25-gauge or larger needle and inject slowly (1-2 mL per injection) using a moving needle technique (inject while withdrawing); infiltrate above and below the fascia and into subcutaneous tissue; space injections 1-1.5 cm apart for overlapping coverage; aspirate frequently to avoid intravascular injection. For abdominal procedures (e.g., abdominoplasty/tummy tuck, hernia repair, bariatric surgery), it is often administered via direct infiltration during fascial closure or as a transversus abdominis plane (TAP) block under direct visualization or ultrasound guidance, targeting the fascial plane between the internal oblique and transversus abdominis muscles bilaterally. Key indications for infiltration include surgical procedures such as abdominal (including abdominoplasty, hernia repair, bariatric), breast, orthopedic, and others. Compatibility: Do not admix Exparel with lidocaine or other non-bupivacaine local anesthetics. Wait at least 20 minutes after administration of lidocaine before using Exparel. Admixture with bupivacaine HCl is permitted in a ratio not exceeding 1:2 (mg bupivacaine HCl to mg Exparel). Avoid administration of additional local anesthetics within 96 hours following Exparel use. Precautions: Monitor patients for signs and symptoms of local anesthetic systemic toxicity (LAST), including CNS and cardiovascular effects, and have resuscitation equipment and 20% lipid emulsion immediately available. Exercise caution in patients with hepatic impairment due to potentially reduced clearance. Common adverse reactions (from clinical trials): In patients receiving infiltration, common side effects include nausea, constipation, and vomiting. In patients receiving interscalene brachial plexus nerve block, common side effects include nausea, pyrexia, headache, and constipation. Safety considerations: Do not exceed 266 mg; avoid hypotonic diluents; monitor for local anesthetic systemic toxicity (LAST); avoid additional local anesthetics within certain timeframes (consult prescribing information). Exparel is not for intravascular, intraarticular, or certain other uses. The potential sensory and/or motor loss with Exparel is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days as seen in clinical trials. Patients should be informed in advance of possible temporary loss of sensation or motor activity lasting up to 5 days. Administration of Exparel results in systemic plasma levels of bupivacaine which can persist for 96 hours after local infiltration and 120 hours after interscalene brachial plexus nerve block (longer in some other nerve blocks). Systemic plasma levels do not correlate directly with local efficacy. In clinical studies, pain relief provided by Exparel lasted from 24 to 72 hours, varying by surgery type, dose, and individual factors. The manufacturer describes it as providing pain control for up to 4 of the toughest days post-surgery through gradual release. In obstetric procedures such as cesarean delivery, Exparel has been studied primarily via transversus abdominis plane (TAP) blocks or surgical site infiltration as part of multimodal analgesia regimens, often including intrathecal morphine, acetaminophen, and NSAIDs. Although not specifically FDA-approved for cesarean delivery, manufacturer guidance includes C-section under OB/GYN procedures suitable for the 266 mg dose via fascial plane blocks like TAP. A key Phase 4 randomized controlled trial (Nedeljkovic et al., published in Anesthesia and Analgesia, 2020) evaluated bilateral TAP blocks in elective cesarean patients under spinal anesthesia. Patients received a total of 266 mg Exparel admixed with 50 mg bupivacaine HCl, plus normal saline for volume expansion, divided bilaterally and administered under ultrasound guidance post-delivery. This regimen achieved a statistically significant 52% reduction in total opioid consumption through 72 hours compared to bupivacaine HCl alone (least squares mean 15.5 mg vs. 32.0 mg oral morphine equivalents; P=0.0117), along with a higher percentage of opioid-spared patients. Pain control was comparable between groups. Other trials have shown mixed results for incisional infiltration (e.g., 266 mg Exparel into fascia/skin before closure), with some finding no significant difference in pain scores or opioid use versus placebo when added to multimodal therapy including intrathecal morphine. Admixture follows general rules (ratio of bupivacaine HCl to Exparel ≤1:2 by milligram dose), with total bupivacaine equivalents monitored. Exparel is contraindicated for obstetrical paracervical block anesthesia, consistent with warnings for bupivacaine products due to risks like fetal bradycardia. Pharmacokinetic studies confirm detectable bupivacaine in maternal plasma and breast milk post-TAP block, warranting caution during lactation though clinical impact on infants is unclear. These applications highlight Exparel's role in opioid-sparing strategies for post-cesarean pain, though evidence varies by technique and background analgesia. Pediatric Use For pediatric patients aged 6 years and older, the recommended dose of Exparel for single-dose local infiltration is weight-based at 4 mg/kg, not to exceed a maximum of 266 mg (20 mL of the 1.3% suspension). The dose is calculated as: dose (mg) = body weight (kg) × 4 mg/kg. The volume is then determined by dividing the mg dose by the concentration (13.3 mg/mL). This dosing is derived from pharmacokinetic and safety studies in pediatric patients undergoing spine or cardiac surgery. The exact volume is determined primarily by body weight, but also considers the surgical site's size and the need for adequate infiltration coverage. Exparel may be diluted with normal saline or lactated Ringer’s solution (up to 300 mL total volume for the 266 mg dose) to improve spread and coverage, while maintaining a minimum concentration of 0.89 mg/mL. It can be admixed with bupivacaine HCl in a ratio not exceeding 1:2 (mg bupivacaine HCl to mg Exparel) to provide earlier onset of analgesia. Administration requires slow injection (typically 1–2 mL per site) with frequent aspiration to avoid intravascular injection. Considerations include patient hepatic and renal function, as bupivacaine is metabolized in the liver and excreted renally. Studies show plasma levels remain below toxic thresholds, but monitoring for signs of local anesthetic systemic toxicity (LAST) remains essential. The maximum dose of 266 mg applies to patients weighing approximately 66.5 kg and above. Exparel is not recommended for infiltration in children under 6 years of age or for nerve blocks in patients under 18 years of age. [41] Efficacy comparisons Evidence on Exparel's superiority over plain long-acting local anesthetics (e.g., bupivacaine HCl or ropivacaine) or other non-opioid options (continuous catheter infusions like ON-Q pumps, multimodal regimens with acetaminophen/NSAIDs/gabapentinoids) is mixed. While designed for prolonged analgesia to reduce opioid reliance in enhanced recovery protocols, systematic reviews and meta-analyses of dozens of RCTs (e.g., up to 77 trials encompassing thousands of patients) indicate that liposomal bupivacaine does not consistently demonstrate clinically meaningful benefits in postoperative pain scores (at 24-72 hours) or opioid consumption compared to